MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

01 Aug 2025 Evaluate
The revenue zoomed 14.57% to Rs. 1008.58 millions for the quarter ended June 2025 as compared to Rs. 880.34 millions during the corresponding quarter last year.The Net Profit of the company registered a slight decline of -2.31% to Rs. 76.45  millions from Rs. 78.26 millions.Operating Profit saw a handsome growth to 143.71 millions from 125.85 millions in the quarter ended June 2025.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 1008.58 880.34 14.57 1008.58 880.34 14.57 3592.94 3289.73 9.22
Other Income 65.53 62.67 4.56 65.53 62.67 4.56 97.58 159.01 -38.63
PBIDT 143.71 125.85 14.19 143.71 125.85 14.19 354.59 601.94 -41.09
Interest 12.08 4.43 172.69 12.08 4.43 172.69 23.07 13.38 72.42
PBDT 131.63 121.42 8.41 131.63 121.42 8.41 331.52 588.56 -43.67
Depreciation 34.47 21.40 61.07 34.47 21.40 61.07 92.70 81.48 13.77
PBT 97.16 100.02 -2.86 97.16 100.02 -2.86 238.82 507.08 -52.90
TAX 20.71 21.76 -4.83 20.71 21.76 -4.83 57.50 121.89 -52.83
Deferred Tax 13.52 3.51 285.19 13.52 3.51 285.19 4.06 7.76 -47.68
PAT 76.45 78.26 -2.31 76.45 78.26 -2.31 181.32 385.19 -52.93
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 14.25 14.30 -0.33 14.25 14.30 -0.33 9.87 18.30 -46.06
Peers
Company Name CMP
Sun Pharma. Inds. 1853.00
Dr. Reddys Labs. 1200.40
Cipla 1404.00
Lupin 2098.00
Zydus Lifesciences 1180.00
View more..